NovoCure Limited (NVCR) CEO Asaf Danziger on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/29/21
Novocure Reports Second Quarter 2021 Financial Results and Provides Company UpdateBusiness Wire • 07/29/21
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research ProgramBusiness Wire • 07/15/21
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver CancerBusiness Wire • 07/01/21
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent GlioblastomaBusiness Wire • 05/25/21
Novocure Gets FDA Approval For Reducing Sample Size For Late-Stage Pivotal LUNAR Lung Cancer StudyBenzinga • 05/18/21
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung CancerBusiness Wire • 05/18/21